{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:19:35Z","timestamp":1792163975534,"version":"4.4.0"},"reference-count":256,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety disorders. This review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (PD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific phobias (SP), including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), azapirones (e.g., buspirone), mixed antidepressants (e.g., mirtazapine), antipsychotics, antihistamines (e.g., hydroxyzine), alpha- and beta-adrenergic medications (e.g., propranolol, clonidine), and GABAergic medications (benzodiazepines, pregabalin, and gabapentin). Posttraumatic stress disorder and obsessive-compulsive disorder are excluded from this review. Second, we will review novel pharmacotherapeutic agents under investigation for the treatment of anxiety disorders in adults. The pathways and neurotransmitters reviewed include serotonergic agents, glutamate modulators, GABAergic medications, neuropeptides, neurosteroids, alpha- and beta-adrenergic agents, cannabinoids, and natural remedies. The outcome of the review reveals a lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents. Although there are some recent randomized controlled trials for novel agents including neuropeptides, glutamatergic agents (such as ketamine and d-cycloserine), and cannabinoids (including cannabidiol) primarily in GAD or SAD, these trials have largely been negative, with only some promise for kava and PH94B (an inhaled neurosteroid). Overall, the progression of current and future psychopharmacology research in anxiety disorders suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.<\/jats:p>","DOI":"10.3389\/fpsyt.2020.595584","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:08:41Z","timestamp":1608696521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":346,"title":["Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options"],"prefix":"10.3389","volume":"11","author":[{"given":"Amir","family":"Garakani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Murrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael C.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn P.","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank D.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan V.","family":"Iosifescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"B2","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jad.2011.05.028","article-title":"Common mental disorders and subsequent work disability: a population-based health 2000 study","volume":"134","author":"Ahola","year":"2011","journal-title":"J Affect Disord."},{"key":"B4","first-page":"193","article-title":"Costs of nine common mental disorders: implications for curative and preventive psychiatry","volume":"9","author":"Smit","year":"2006","journal-title":"J Ment Health Policy Econ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1600-0047.2004.00329.x","article-title":"Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project","volume":"2004","author":"Alonso","year":"2004","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.nmd.0000198140.02154.32","article-title":"Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients","volume":"194","author":"Rodriguez","year":"2006","journal-title":"J Nerv Ment Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","article-title":"Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study","volume":"162","author":"Bruce","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2015.17.2\/proybyrne","article-title":"Treatment-refractory anxiety; definition, risk factors, and treatment challenges","volume":"17","author":"Roy-Byrne","year":"2015","journal-title":"Dialogues Clin Neurosci."},{"key":"B10","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1126\/science.aap8757","article-title":"Analysis of shared heritability in common disorders of the brain","volume":"360","author":"Anttila","year":"2018","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"B14","volume-title":"Practice Guideline for the Treatment of Patients with Panic Disorder","year":"2009"},{"key":"B15","unstructured":"Generalised Anxiety Disorder and Panic Disordr in Adults: Management"},{"key":"B16","unstructured":"Social Anxiety Disorder: Recognition, Assessment and Treatment"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2019.08.009","article-title":"Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis","volume":"118","author":"He","year":"2019","journal-title":"J Psychiatr Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jamapsychiatry.2019.2859","article-title":"Association of antidepressant use with adverse health outcomes: a systematic umbrella review","volume":"76","author":"Dragioti","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1192\/bjp.bp.107.048371","article-title":"Antidepressant-induced jitteriness\/anxiety syndrome: systematic review","volume":"194","author":"Sinclair","year":"2009","journal-title":"Br J Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","article-title":"SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis","volume":"106","author":"Bakker","year":"2002","journal-title":"Acta Psychiatr Scand."},{"key":"B21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14656566.2017.1285907","article-title":"A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators","volume":"18","author":"Curtiss","year":"2017","journal-title":"Expert Opin Pharmacother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"Cd006115","DOI":"10.1002\/14651858.CD006115","article-title":"Azapirones for generalized anxiety disorder","volume":"2006","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"Cd010828","DOI":"10.1002\/14651858.CD010828.pub2","article-title":"Azapirones versus placebo for panic disorder in adults","volume":"2014","author":"Imai","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.14712\/23362936.2020.1","article-title":"Buspirone-associated movement disorder: a literature review","volume":"121","author":"Rissardo","year":"2020","journal-title":"Prague Med Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00004714-199906000-00012","article-title":"Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors","volume":"19","author":"Land\u00e9n","year":"1999","journal-title":"J Clin Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1743-6109.2010.02190.x","article-title":"The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature","volume":"8","author":"Moll","year":"2011","journal-title":"J Sexual Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","article-title":"Mirtazapine: a review of its use in major depression and other psychiatric disorders","volume":"23","author":"Croom","year":"2009","journal-title":"CNS Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro","year":"2001","journal-title":"Braz J Med Biol Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/01.jcp.0000186871.04984.8d","article-title":"Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Muehlbacher","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/YIC.0b013e32833a4d71","article-title":"Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Schutters","year":"2010","journal-title":"Int Clin Psychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4088\/JCP.v62n1005","article-title":"Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?","volume":"62","author":"Trivedi","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2007.05.012","article-title":"Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials","volume":"42","author":"Papakostas","year":"2008","journal-title":"J Psychiatr Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4088\/JCP.v69n0812","article-title":"Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies","volume":"69","author":"Papakostas","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B34","first-page":"46","article-title":"A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder","volume":"41","author":"Bystritsky","year":"2008","journal-title":"Psychopharmacol Bull."},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004714-198302000-00006","article-title":"Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias","volume":"3","author":"Sheehan","year":"1983","journal-title":"J Clin Psychopharmacol"},{"key":"B36","first-page":"66","article-title":"Bupropion sustained release for panic disorder","volume":"37","author":"Simon","year":"2003","journal-title":"Psychopharmacol Bull."},{"key":"B37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00004714-200010000-00009","article-title":"Efficacy of open-label nefazodone treatment in patients with panic disorder","volume":"20","author":"Papp","year":"2000","journal-title":"J Clin Psychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<137::AID-DA8>3.0.CO;2-7","article-title":"Pilot open-label study of nefazodone in panic disorder","volume":"10","author":"Bystritsky","year":"1999","journal-title":"Depress Anxiety."},{"key":"B39","first-page":"245","article-title":"An open-label trial of nefazodone in high comorbidity panic disorder","volume":"57","author":"DeMartinis","year":"1996","journal-title":"J Clin Psychiatry."},{"key":"B40","first-page":"671","article-title":"An open trial of nefazodone in adult patients with generalized anxiety disorder","volume":"32","author":"Hedges","year":"1996","journal-title":"Psychopharmacol Bull."},{"key":"B41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4088\/JCP.v68n0215","article-title":"Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial","volume":"68","author":"Van Ameringen","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","article-title":"Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015","volume":"20","author":"Torres-Bondia","year":"2020","journal-title":"BMC Public Health."},{"key":"B44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-981-32-9705-0_20","article-title":"Role of benzodiazepines in anxiety disorders","volume":"1191","author":"Balon","year":"2020","journal-title":"Adv Exp Med Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamapsychiatry.2014.2190","article-title":"Why are benzodiazepines not yet controlled substances?","volume":"72","author":"Moore","year":"2015","journal-title":"JAMA Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin Pharmacother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000353198","article-title":"Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis","volume":"82","author":"Offidani","year":"2013","journal-title":"Psychother Psychosom."},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/YIC.0000000000000276","article-title":"Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis","volume":"34","author":"Shinfuku","year":"2019","journal-title":"Int Clin Psychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1176\/appi.ajp.2019.19030315","article-title":"Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study","volume":"177","author":"Osler","year":"2020","journal-title":"Am J Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0000000000000316","article-title":"Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology","volume":"35","author":"Lim","year":"2020","journal-title":"Int Clin Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/jcp.0b013e318059361a","article-title":"The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence","volume":"27","author":"Mula","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"Int Clin Psychopharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/13543784.2014.979283","article-title":"Pregabalin for the treatment of social anxiety disorder","volume":"24","author":"Kawalec","year":"2015","journal-title":"Expert Opin Investig Drugs."},{"key":"B54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0b013e3283491fd5","article-title":"Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study","volume":"26","author":"Greist","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":"Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study","volume":"24","author":"Pande","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/YIC.0b013e32834519bd","article-title":"Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study","volume":"26","author":"Feltner","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Res Social Adm Pharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/cns.13115","article-title":"Pregabalin: a range of misuse-related unanswered questions","volume":"25","author":"Schifano","year":"2019","journal-title":"CNS Neurosci Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jat\/bkz036","article-title":"Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study","volume":"43","author":"Nahar","year":"2019","journal-title":"J Anal Toxicol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"19r02465","DOI":"10.4088\/PCC.19r02465","article-title":"Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review","volume":"21","author":"Ahmed","year":"2019","journal-title":"Prim Care Companion CNS Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front Psychiatry."},{"key":"B62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder","volume":"20","author":"Pande","year":"2000","journal-title":"J Clin Psychopharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0269881103017002006","article-title":"Effects of gabapentin on anxiety induced by simulated public speaking","volume":"17","author":"de-Paris","year":"2003","journal-title":"J Psychopharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction."},{"key":"B65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s007020200071","article-title":"Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats","volume":"109","author":"Schmitt","year":"2002","journal-title":"J Neural Transm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/JCP.0b013e318172b45f","article-title":"Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies","volume":"28","author":"Pollack","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0029-1241798","article-title":"Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder","volume":"42","author":"Zwanzger","year":"2009","journal-title":"Pharmacopsychiatry."},{"key":"B68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4088\/PCC.08l00641","article-title":"Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults","volume":"11","author":"Urbano","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00213-005-2146-1","article-title":"Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?","volume":"180","author":"Mirza","year":"2005","journal-title":"Psychopharmacology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/WNF.0b013e3181d4c1f6","article-title":"Lamotrigine administration in panic disorder with agoraphobia","volume":"33","author":"Masdrakis","year":"2010","journal-title":"Clin Neuropharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2165\/00003495-200464190-00004","article-title":"Antiepileptic drugs in the treatment of anxiety disorders: role in therapy","volume":"64","author":"Van Ameringen","year":"2004","journal-title":"Drugs."},{"key":"B72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","article-title":"Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study","volume":"23","author":"Aliyev","year":"2008","journal-title":"Eur Psychiatry."},{"key":"B73","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00004850-200305000-00008","article-title":"Valproic acid for the treatment of social anxiety disorder","volume":"18","author":"Kinrys","year":"2003","journal-title":"Int Clin Psychopharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","article-title":"Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial","volume":"71","author":"Stein","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0269881105056526","article-title":"Levetiracetam in social phobia: a placebo controlled pilot study","volume":"19","author":"Zhang","year":"2005","journal-title":"J Psychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"Cd006815","DOI":"10.1002\/14651858.CD006815.pub2","article-title":"Hydroxyzine for generalised anxiety disorder","volume":"2010","author":"Guaiana","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B78","first-page":"20","article-title":"Pharmacotherapy of social anxiety disorder: what does the evidence tell us?","volume":"67","author":"Davidson","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/archpsyc.1986.01800110028005","article-title":"Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder","volume":"43","author":"Charney","year":"1986","journal-title":"Arch Gen Psychiatry."},{"key":"B80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/cap.2016.0132","article-title":"Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial","volume":"27","author":"Strawn","year":"2017","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/archpsyc.1989.01810020072012","article-title":"Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder","volume":"46","author":"Uhde","year":"1989","journal-title":"Arch Gen Psychiatry."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/archpsyc.1981.01780360094011","article-title":"Effects of clonidine on anxiety disorders","volume":"38","author":"Hoehn-Saric","year":"1981","journal-title":"Arch Gen Psychiatry."},{"key":"B83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1399-6576.2006.00940.x","article-title":"Clonidine in paediatric anaesthesia: review of the literature and comparison with benzodiazepines for premedication","volume":"50","author":"Bergendahl","year":"2006","journal-title":"Acta Anaesthesiol Scand."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA."},{"key":"B85","doi-asserted-by":"publisher","first-page":"Cd008120","DOI":"10.1002\/14651858.CD008120.pub2","article-title":"Second-generation antipsychotics for anxiety disorders","volume":"2010","author":"Depping","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B86","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/JCP.0b013e31821b2b3f","article-title":"Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis","volume":"31","author":"LaLonde","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/ijms17040551","article-title":"Is there room for second-generation antipsychotics in the pharmacotherapy of panic disorder? A systematic review based on PRISMA guidelines","volume":"17","author":"Perna","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"B90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajp.2017.01.016","article-title":"Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis","volume":"26","author":"Zareifopoulos","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B91","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/da.22693","article-title":"A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder","volume":"34","author":"Schneier","year":"2017","journal-title":"Depress Anxiety."},{"key":"B93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4088\/PCC.15m01831","article-title":"A 12-week doubleblind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder","author":"Careri","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2147\/NDT.S103408","article-title":"Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies","volume":"12","author":"Clayton","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2174\/1389450118666171117131151","article-title":"Vortioxetine treatment for anxiety disorder: a meta-analysis study","volume":"19","author":"Yee","year":"2018","journal-title":"Curr Drug Targets."},{"key":"B96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","article-title":"Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder","volume":"27","author":"Baldwin","year":"2012","journal-title":"Int Clin Psychopharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e033161","DOI":"10.1136\/bmjopen-2019-033161","article-title":"Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes","volume":"9","author":"Qin","year":"2019","journal-title":"BMJ Open."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12991-018-0190-6","article-title":"An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder","volume":"17","author":"Shah","year":"2018","journal-title":"Ann Genrl Psychiatry."},{"key":"B100","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT 1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs."},{"key":"B101","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00004714-199304000-00009","article-title":"Gepirone and the treatment of panic disorder: an open study","volume":"13","author":"Pecknold","year":"1993","journal-title":"J Clin Psychopharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1358\/dot.2019.55.7.2958474","article-title":"Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties","volume":"55","author":"Kaur Gill","year":"2019","journal-title":"Drugs Today."},{"key":"B103","unstructured":"Fabre-Kramer PharmaceuticalsI\n          Travivo\u2122 for Generalized Anxiety Disorder."},{"key":"B104","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00044011-200424020-00007","article-title":"Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial","volume":"24","author":"Nishitsuji","year":"2004","journal-title":"Clin Drug Investig."},{"key":"B105","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jpsychires.2018.01.020","article-title":"Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, open-label study","volume":"99","author":"Lin","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0b013e31816774de","article-title":"Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial","volume":"28","author":"Rickels","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B107","unstructured":"Fabre-Kramer PharmaceuticalsI\n          FKW00GA."},{"key":"B108","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/FBP.0b013e3282d28f9c","article-title":"Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats","volume":"18","author":"Weso\u0142owska","year":"2007","journal-title":"Behav Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-151146","article-title":"AVN-101: a multi-target drug candidate for the treatment of CNS disorders","volume":"53","author":"Ivachtchenko","year":"2016","journal-title":"J Alzheimers Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/(SICI)1520-6394(1997)5:3<140::AID-DA7>3.0.CO;2-I","article-title":"Efficacy of ondansetron in the treatment of generalized anxiety disorder","volume":"5","author":"Freeman","year":"1997","journal-title":"Depress Anxiety."},{"key":"B111","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<199::AID-ANXI7>3.0.CO;2-J","article-title":"Ondansetron in the treatment of panic disorder","volume":"2","author":"Schneier","year":"1996","journal-title":"Anxiety."},{"key":"B112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1517\/14656566.2014.862233","article-title":"The mechanism, efficacy, and tolerability profile of agomelatine","volume":"15","author":"MacIsaac","year":"2014","journal-title":"Expert Opin Pharmacother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.euroneuro.2018.05.006","article-title":"12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg\/day) versus escitalopram (10-20 mg\/day) in out-patients with severe generalized anxiety disorder","volume":"28","author":"Stein","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B116","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","article-title":"Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study","volume":"27","author":"Stein","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study","volume":"73","author":"Stein","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/da.23065","article-title":"Historic psychedelic drug trials and the treatment of anxiety disorders","author":"Weston","year":"2020","journal-title":"Depress Anxiety."},{"key":"B119","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2019","journal-title":"Front Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/11533230-000000000-00000","article-title":"Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists","volume":"24","author":"Krystal","year":"2010","journal-title":"CNS Drugs."},{"key":"B121","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"B123","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B124","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B125","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry."},{"key":"B128","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B129","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B130","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol Psychiatry."},{"key":"B131","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B132","doi-asserted-by":"publisher","first-page":"19r12889","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B133","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.neuroscience.2009.03.038","article-title":"Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models","volume":"161","author":"Engin","year":"2009","journal-title":"Neuroscience."},{"key":"B134","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial","volume":"16","author":"Irwin","year":"2013","journal-title":"J Palliat Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B138","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1176\/appi.ajp.161.1.171","article-title":"An open-label trial of riluzole in patients with treatment-resistant major depression","volume":"161","author":"Zarate","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B139","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.biopsych.2006.08.037","article-title":"Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms","volume":"61","author":"Sanacora","year":"2007","journal-title":"Biol Psychiatry."},{"key":"B140","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int J Neuropsychopharmacol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.neuropharm.2012.02.012","article-title":"Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines","volume":"62","author":"Sugiyama","year":"2012","journal-title":"Neuropharmacology."},{"key":"B142","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF00589901","article-title":"Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats","volume":"99","author":"Stutzmann","year":"1989","journal-title":"Psychopharmacology."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B144","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.biopsych.2007.09.012","article-title":"Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder","volume":"63","author":"Mathew","year":"2008","journal-title":"Biol Psychiatry."},{"key":"B145","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.euroneuro.2012.05.009","article-title":"A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD","volume":"23","author":"Abdallah","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/npp.2010.88","article-title":"Glutamate receptors in extinction and extinction-based therapies for psychiatric illness","volume":"36","author":"Myers","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"J Psychopharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2006.03.084","article-title":"Effects of D-cycloserine on extinction: translation from preclinical to clinical work","volume":"60","author":"Davis","year":"2006","journal-title":"Biol Psychiatry."},{"key":"B149","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1017\/S1461145702003061","article-title":"Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder","volume":"5","author":"Heresco-Levy","year":"2002","journal-title":"Int J Neuropsychopharmacol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00213-007-0817-9","article-title":"D-Cycloserine and performance under different states of anxiety in healthy volunteers","volume":"193","author":"Bailey","year":"2007","journal-title":"Psychopharmacology."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.biopsych.2010.01.022","article-title":"The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans","volume":"67","author":"Onur","year":"2010","journal-title":"Biol Psychiatry."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4088\/JCP.11m07564","article-title":"Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study","volume":"73","author":"Nave","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"B153","doi-asserted-by":"publisher","first-page":"CD007803","DOI":"10.1002\/14651858.CD007803.pub2","article-title":"Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders","volume":"2015","author":"Ori","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B154","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","article-title":"D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data","volume":"74","author":"Mataix-Cols","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B155","doi-asserted-by":"publisher","first-page":"103607","DOI":"10.1016\/j.brat.2020.103607","article-title":"Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: a randomized placebo-controlled trial","volume":"129","author":"Reinecke","year":"2020","journal-title":"Behav Res Therapy"},{"key":"B156","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0000000000000757","article-title":"No effects of D-cycloserine enhancement in exposure with response prevention therapy in panic disorder with agoraphobia: a double-blind, randomized controlled trial","volume":"37","author":"Hofmeijer-Sevink","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.janxdis.2017.11.004","article-title":"Does d-cycloserine facilitate the effects of homework compliance on social anxiety symptom reduction?","volume":"53","author":"Roque","year":"2018","journal-title":"J Anxiety Disord."},{"key":"B158","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/archpsyc.63.3.298","article-title":"Augmentation of exposure therapy with D-cycloserine for social anxiety disorder","volume":"63","author":"Hofmann","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B159","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2007.11.011","article-title":"A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder","volume":"63","author":"Guastella","year":"2008","journal-title":"Biol Psychiatry."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e206777","DOI":"10.1001\/jamanetworkopen.2020.6777","article-title":"Dose timing of D-cycloserine to augment exposure therapy for social anxiety disorder: a randomized clinical trial","volume":"3","author":"Smits","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B161","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1176\/appi.ajp.2013.12070974","article-title":"D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder","volume":"170","author":"Hofmann","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e0223729","DOI":"10.1371\/journal.pone.0223729","article-title":"Effect of d-cycloserine on fear extinction training in adults with social anxiety disorder","volume":"14","author":"Hofmann","year":"2019","journal-title":"PLoS ONE."},{"key":"B163","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jpsychires.2012.09.024","article-title":"Augmentation of exposure therapy with post-session administration of D-cycloserine","volume":"47","author":"Tart","year":"2013","journal-title":"J Psychiatr Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch Gen Psychiatry."},{"key":"B165","doi-asserted-by":"publisher","first-page":"101546","DOI":"10.1016\/j.jbtep.2019.101546","article-title":"D-cycloserine as adjunct to brief computerised CBT for spider fear: effects on fear, behaviour, and cognitive biases","volume":"68","author":"Kappelmann","year":"2020","journal-title":"J Behav Ther Exp Psychiatry."},{"key":"B166","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/16506073.2012.711770","article-title":"The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals","volume":"41","author":"Gutner","year":"2012","journal-title":"Cogn Behav Ther."},{"key":"B167","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jpsychires.2006.05.006","article-title":"A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear","volume":"41","author":"Guastella","year":"2007","journal-title":"J Psychiatr Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs."},{"key":"B169","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol Bull."},{"key":"B170","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nm0498-460","article-title":"Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin","volume":"4","author":"Jevtovi\u0107-Todorovi\u0107","year":"1998","journal-title":"Nat Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/ajad.12372","article-title":"Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature","volume":"25","author":"Garakani","year":"2016","journal-title":"Am J Addict."},{"key":"B172","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1874473711666181008163107","article-title":"Mini-review: a brief history of nitrous oxide (N2O) use in neuropsychiatry","volume":"11","author":"Gillman","year":"2019","journal-title":"Curr Drug Res Rev."},{"key":"B173","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol Psychiatry."},{"key":"B174","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.janxdis.2013.04.002","article-title":"A critical review of approaches to the treatment of dental anxiety in adults","volume":"27","author":"Gordon","year":"2013","journal-title":"J Anxiety Disord."},{"key":"B175","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pharmthera.2009.09.001","article-title":"Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA","volume":"125","author":"Atack","year":"2010","journal-title":"Pharmacol Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/JCP.0000000000000997","article-title":"An 8-week, randomized, phase 2, double-blind, sequential parallel-group comparison study of two dose levels of the GABAA positive allosteric modulator PF-06372865 compared with placebo as an adjunctive treatment in outpatients with inadequate response to standard of care for generalized anxiety disorder","volume":"39","author":"Simen","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.biopsych.2019.12.013","article-title":"Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder","volume":"87","author":"Wise","year":"2020","journal-title":"Biol Psychiatry."},{"key":"B178","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000496086","article-title":"Novel benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles","volume":"5","author":"Prevot","year":"2019","journal-title":"Mol Neuropsychiatry."},{"key":"B179","unstructured":"2019"},{"key":"B180","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABA(A) receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"B181","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fnins.2013.00035","article-title":"Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders","volume":"7","author":"Macdonald","year":"2013","journal-title":"Front Neurosci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881108095705","article-title":"Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers","volume":"23","author":"Di Simplicio","year":"2009","journal-title":"J Psychopharmacol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11920-017-0819-1","article-title":"Oxytocin and anxiety disorders: translational and therapeutic aspects","volume":"19","author":"Naja","year":"2017","journal-title":"Curr Psychiatry Rep."},{"key":"B184","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/da.22362","article-title":"Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response","volume":"32","author":"Acheson","year":"2015","journal-title":"Depression Anxiety."},{"key":"B185","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-981-32-9705-0_7","article-title":"The role of the oxytocin system in anxiety disorders","volume":"1191","author":"Yoon","year":"2020","journal-title":"Adv Exp Med Biol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/7854_2017_25","article-title":"Oxytocin and anxiety disorders","volume":"35","author":"Gottschalk","year":"2018","journal-title":"Curr Top Behav Neurosci."},{"key":"B187","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/npp.2014.168","article-title":"Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder","volume":"40","author":"Gorka","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"B188","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.biopsycho.2017.05.015","article-title":"Working hard for oneself or others: effects of oxytocin on reward motivation in social anxiety disorder","volume":"127","author":"Fang","year":"2017","journal-title":"Biol Psychol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.psyneuen.2016.10.013","article-title":"Effects of intranasal oxytocin on symptoms of schizophrenia: a multivariate Bayesian meta-analysis","volume":"75","author":"Williams","year":"2017","journal-title":"Psychoneuroendocrinology."},{"key":"B190","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neubiorev.2017.05.007","article-title":"Oxytocin effects in schizophrenia: reconciling mixed findings and moving forward","volume":"80","author":"Bradley","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"key":"B191","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neubiorev.2017.04.017","article-title":"The correlation between central and peripheral oxytocin concentrations: a systematic review and meta-analysis","volume":"78","author":"Valstad","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"key":"B192","doi-asserted-by":"publisher","first-page":"101993","DOI":"10.1016\/j.npep.2019.101993","article-title":"Substance P: a neuropeptide involved in the psychopathology of anxiety disorders","volume":"79","author":"Iftikhar","year":"2020","journal-title":"Neuropeptides."},{"key":"B193","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00726-006-0335-9","article-title":"The role of substance P in stress and anxiety responses","volume":"31","author":"Ebner","year":"2006","journal-title":"Amino Acids."},{"key":"B194","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.euroneuro.2009.10.005","article-title":"Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder","volume":"20","author":"Tauscher","year":"2010","journal-title":"Eur Neuropsychopharmacol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145712000065","article-title":"Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder","volume":"16","author":"Michelson","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1038\/tp.2015.92","article-title":"Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171","volume":"5","author":"Frick","year":"2015","journal-title":"Transl Psychiatry."},{"key":"B197","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa054.","article-title":"A randomized controlled trial of intranasal neuropeptide y in patients with major depressive disorder","author":"Math\u00e9","year":"2020","journal-title":"Int J Neuropsychopharmacol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"319","DOI":"10.13918\/j.issn.2095-8137.2014.4.319","article-title":"AVP and Glu systems interact to regulate levels of anxiety in BALB\/cJ mice","volume":"35","author":"An","year":"2014","journal-title":"Dongwuxue Yanjiu."},{"key":"B201","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4088\/JCP.12m07804","article-title":"The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies","volume":"73","author":"Griebel","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"B203","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J Pharm Sci."},{"key":"B204","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fnsys.2013.00100","article-title":"A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study","volume":"7","author":"Lee","year":"2013","journal-title":"Front Syst Neurosci."},{"key":"B205","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/da.21919","article-title":"Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin","volume":"29","author":"Zwanzger","year":"2012","journal-title":"Depress Anxiety."},{"key":"B206","doi-asserted-by":"publisher","first-page":"109761","DOI":"10.1016\/j.pnpbp.2019.109761","article-title":"Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat","volume":"96","author":"Ballaz","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B207","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.yhbeh.2006.06.019","article-title":"Role of corticotropin releasing factor in anxiety disorders: a translational research perspective","volume":"50","author":"Risbrough","year":"2006","journal-title":"Horm Behav."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1177\/0269881111400650","article-title":"Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety","volume":"25","author":"Bailey","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","article-title":"Don't stress about CRF: assessing the translational failures of CRF(1)antagonists","volume":"234","author":"Spierling","year":"2017","journal-title":"Psychopharmacology."},{"key":"B210","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depress Anxiety."},{"key":"B211","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/npp.2016.61","article-title":"The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects","volume":"41","author":"Schwandt","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/npp.2014.306","article-title":"The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study","volume":"40","author":"Kwako","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"B213","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.yfrne.2018.06.003","article-title":"Orexins and stress","volume":"51","author":"Grafe","year":"2018","journal-title":"Front Neuroendocrinol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neuropharm.2018.09.034","article-title":"The role of the orexin system in stress response","volume":"154","author":"Sargin","year":"2019","journal-title":"Neuropharmacology."},{"key":"B215","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.physbeh.2012.04.016","article-title":"Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network","volume":"107","author":"Johnson","year":"2012","journal-title":"Physiol Behav."},{"key":"B216","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci Bull."},{"key":"B217","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.2174\/138161208786848838","article-title":"Neuroactive steroids as endogenous modulators of anxiety","volume":"14","author":"Eser","year":"2008","journal-title":"Curr Pharm Des."},{"key":"B218","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fendo.2011.00055","article-title":"Neurosteroids as neuromodulators in the treatment of anxiety disorders","volume":"2","author":"Longone","year":"2011","journal-title":"Front Endocrinol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00213-005-0213-2","article-title":"Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake","volume":"186","author":"Pinna","year":"2006","journal-title":"Psychopharmacology."},{"key":"B220","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/gps.4085","article-title":"Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone","volume":"29","author":"Lenze","year":"2014","journal-title":"Int J Geriatr Psychiatry."},{"key":"B221","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Am J Psychiatry."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/da.22546","article-title":"Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder","volume":"33","author":"Liebowitz","year":"2016","journal-title":"Depression Anxiety."},{"key":"B223","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B224","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"B226","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front Psychol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.pnpbp.2010.02.028","article-title":"Neuroimaging in social anxiety disorder: a systematic review of the literature","volume":"34","author":"Freitas-Ferrari","year":"2010","journal-title":"Progr Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depress Anxiety."},{"key":"B230","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2001-15191","article-title":"Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance","volume":"34","author":"Muller-Vahl","year":"2001","journal-title":"Pharmacopsychiatry."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12455","article-title":"Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial","volume":"30","author":"Malik","year":"2017","journal-title":"Dis Esophagus."},{"key":"B232","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jpain.2007.10.018","article-title":"Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy","volume":"9","author":"Narang","year":"2008","journal-title":"J Pain."},{"key":"B233","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.39429.619653.80","article-title":"Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study","volume":"336","author":"Frank","year":"2008","journal-title":"BMJ."},{"key":"B234","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10194-012-0490-1","article-title":"Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial","volume":"13","author":"Pini","year":"2012","journal-title":"J Headache Pain."},{"key":"B235","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"J Pain."},{"key":"B236","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","article-title":"An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain","volume":"153","author":"Toth","year":"2012","journal-title":"Pain."},{"key":"B237","doi-asserted-by":"publisher","first-page":"383S","DOI":"10.1002\/j.1552-4604.1981.tb02618.x","article-title":"Single-dose study of nabilone in anxious volunteers","volume":"21","author":"Glass","year":"1981","journal-title":"J Clin Pharmacol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"377S","DOI":"10.1002\/j.1552-4604.1981.tb02617.x","article-title":"The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety","volume":"21","author":"Fabre","year":"1981","journal-title":"J Clin Pharmacol."},{"key":"B239","first-page":"943","article-title":"Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis","volume":"29","author":"Ilaria","year":"1981","journal-title":"Curr Ther Res Clin Exp."},{"key":"B240","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","article-title":"Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis","volume":"65","author":"Rog","year":"2005","journal-title":"Neurology."},{"key":"B241","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0B013E3181633497","article-title":"Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study","volume":"32","author":"Aragona","year":"2009","journal-title":"Clin Neuropharmacol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"J Neurol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ptr.6033","article-title":"Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance","volume":"32","author":"Yeung","year":"2018","journal-title":"Phytotherapy Res."},{"key":"B244","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00023210-200216110-00002","article-title":"Therapeutic potential of kava in the treatment of anxiety disorders","volume":"16","author":"Singh","year":"2002","journal-title":"CNS Drugs."},{"key":"B245","doi-asserted-by":"publisher","first-page":"Cd003383","DOI":"10.1002\/14651858.CD003383","article-title":"Kava extract for treating anxiety","volume":"2003","author":"Pittler","year":"2003","journal-title":"Cochrane Database Syst Rev."},{"key":"B246","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ctcp.2018.09.003","article-title":"The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials","volume":"33","author":"Smith","year":"2018","journal-title":"Complement Ther Clin Pract."},{"key":"B247","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1089\/acm.2018.0001","article-title":"Kava for generalized anxiety disorder: a review of current evidence","volume":"24","author":"Ooi","year":"2018","journal-title":"J Altern Complement Med."},{"key":"B248","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-319-42307-4_2","article-title":"Herbal anxiolytics with sedative actions","volume-title":"Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders","author":"Sarris","year":"2017"},{"key":"B249","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ptr.5940","article-title":"GABA-modulating phytomedicines for anxiety: a systematic review of preclinical and clinical evidence","volume":"32","author":"Savage","year":"2018","journal-title":"Phytother Res."},{"key":"B250","doi-asserted-by":"publisher","first-page":"1037036","DOI":"10.1155\/2019\/1037036","article-title":"Galphimine-B standardized extract versus alprazolam in patients with generalized anxiety disorder: a ten-week, double-blind, randomized clinical trial","volume":"2019","author":"Romero-Cerecero","year":"2019","journal-title":"BioMed Res Int."},{"key":"B251","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/ptr.6349","article-title":"Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: a systematic review and meta-analysis of randomized trials and quasi-randomized trials","volume":"33","author":"Hieu","year":"2019","journal-title":"Phytotherapy Research."},{"key":"B252","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/nutrit\/nuz023","article-title":"Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis","volume":"77","author":"Marx","year":"2019","journal-title":"Nutr Rev."},{"key":"B253","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.focus.12.2.152","article-title":"Advances in psychopharmacology for anxiety disorders","volume":"12","author":"Garakani","year":"2014","journal-title":"FOCUS."},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16030353","article-title":"Using neuroscience to help understand fear and anxiety: a two-system framework","author":"LeDoux","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B255","doi-asserted-by":"publisher","first-page":"17024","DOI":"10.1038\/nrdp.2017.100","article-title":"Anxiety disorders","volume":"3","author":"Craske","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B256","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jpsychires.2019.08.014","article-title":"Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis","volume":"118","author":"Chen","year":"2019","journal-title":"J Psychiatr Res."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.595584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:08:56Z","timestamp":1608696536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.595584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":256,"alternative-id":["10.3389\/fpsyt.2020.595584"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.595584","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"article-number":"595584"}}